China has cut value-added tax (VAT) to 3% on imports, production and sales of the second batch of anti-cancer and rare diseases drugs in a bid to lower costs for patients and boost its pharmaceutical industry, customs said on Thursday.
Source: todayonline.com
Latest Posts in "China"
- China’s PV Export Policy Shift: From Price Competition to Value, Quality, and Industry Consolidation
- New Rules for Input VAT Credit on Long‑Term Assets
- China Extends Preferential Tax Policy for Innovative Enterprise CDRs Through 2027
- Online Sellers Must Register for Tax When Monthly Sales Reach Thresholds, Says Tax Bureau
- Key Changes and Comparative Analysis of China’s New VAT Law Implementation Rules Effective 2026
